Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Ephedrine hydrochloride |
EINECS | 200-074-6 |
CAS No. | 50-98-6 | Density | N/A |
PSA | 32.26000 | LogP | 2.52080 |
Solubility | N/A | Melting Point |
216-220 °C(lit.) |
Formula | C10H15NO.HCl | Boiling Point | 255 °C at 760 mmHg |
Molecular Weight | 201.696 | Flash Point | 85.6 °C |
Transport Information | N/A | Appearance | colourless crystals or white crystalline powder |
Safety | 22-23 | Risk Codes | 22 |
Molecular Structure | Hazard Symbols | Xn | |
Synonyms |
Benzenemethanol,a-[(1S)-1-(methylamino)ethyl]-,hydrochloride, (aR)-(9CI);Benzenemethanol, a-[1-(methylamino)ethyl]-, hydrochloride, [R-(R*,S*)]-;Ephedrine,hydrochloride, (-)- (8CI);(-)-Ephedrin hydrochloride;(-)-Ephedrinehydrochloride;(1R,2S)-(-)-2-Ephedrinium hydrochloride;(1R,2S)-(-)-Ephedrinehydrochloride;(1R,2S)-Ephedrine hydrochloride;Altusin;CPDD 0047;Ephedral;Ephedrine hydrochloride;Ephedrinium chloride;Ephedronguent;L-Ephedrinehydrochloride;L-erythro-Ephedrine hydrochloride;Sanedrine;l-Ephedrine hydrochloride; |
Article Data | 13 |
The Ephedrine hydrochloride is an organic compound with the formula C10H15NO.HCl. The IUPAC name of this chemical is (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol hydrochloride. With the CAS registry number 50-98-6, it is also named as (1R,2S)-Ephedrine Hydrochloride. The product's classification codes are Bronchodilator; Drug / Therapeutic Agent; Human Data. Besides, it is a colourless crystals or white crystalline powder, which should be stored in a closed cool and dry place. It is used as a stimulant, appetite suppressant, oncentration aid, decongestant, and to treat hypotension associated with anaesthesia.
Physical properties of Ephedrine hydrochloride:
(1)ACD/LogP: 1.05; (2)ACD/LogD (pH 5.5): -1.99; (3)ACD/LogD (pH 7.4): -0.96; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 2; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 4; (11)Polar Surface Area: 12.47 Å2; (12)Flash Point: 85.6 °C; (13)Enthalpy of Vaporization: 52.03 kJ/mol; (14)Boiling Point: 255 °C at 760 mmHg; (15)Vapour Pressure: 0.00865 mmHg at 25°C.
Uses of Ephedrine hydrochloride:
Ephedrine hydrochloride is used to treat and prevent breathing difficulties due to asthma.It is a sympathomimetic agent, sometimes known as an adrenoreceptor agonist or bronchodilator. It is used to open up the airways by relaxing the smooth muscles in the lungs to help people with asthma breathe more easily. In an asthma attack, the lung smooth muscle contracts making it difficult to breathe properly. Ephedrine hydrochloride relaxes the lung smooth muscle, but also makes the smooth muscle of blood vessels narrow leading to side effects. In general this drug is used to treat and prevent asthma, but is less widely used than selective ß2 agonist such as salbutamol and terbutaline due to its safety profile. Benefits of being on this drug can include relief from symptoms such as chest tightness, breathlessness, wheezing and cough.
Safety information of Ephedrine hydrochloride:
When you are using Ephedrine hydrochloride please be cautious about it as the following:It is harmful if swallowed. When you are using it, do not breathe dust and do not breathe gas/fumes/vapour/spray (appropriate wording to be specified by the manufacturer).
You can still convert the following datas into molecular structure:
(1)SMILES: Cl.O[C@H](c1ccccc1)[C@@H](NC)C
(2)InChI: InChI=1/C10H15NO.ClH/c1-8(11-2)10(12)9-6-4-3-5-7-9;/h3-8,10-12H,1-2H3;1H/t8-,10-;/m0./s1
(3)InChIKey: BALXUFOVQVENIU-GNAZCLTHBA
(4)Std. InChI: InChI=1S/C10H15NO.ClH/c1-8(11-2)10(12)9-6-4-3-5-7-9;/h3-8,10-12H,1-2H3;1H/t8-,10-;/m0./s1
(5)Std. InChIKey: BALXUFOVQVENIU-GNAZCLTHSA-N
The toxicity data of Ephedrine hydrochloride is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
cat | LDLo | intravenous | 60mg/kg (60mg/kg) | CARDIAC: OTHER CHANGES | Medecine Vol. 9, Pg. 59, 1930. |
dog | LDLo | intravenous | 70mg/kg (70mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Medecine Vol. 9, Pg. 59, 1930. |
dog | LDLo | subcutaneous | 220mg/kg (220mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Medecine Vol. 9, Pg. 59, 1930. |
frog | LDLo | parenteral | 440mg/kg (440mg/kg) | Manshu Igaku Zasshi. Manchuria Medical Journal. Vol. 3, Pg. 1, 1925. | |
frog | LDLo | subcutaneous | 400mg/kg (400mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Medecine Vol. 9, Pg. 59, 1930. |
guinea pig | LD50 | intravenous | 98mg/kg (98mg/kg) | PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE BEHAVIORAL: EXCITEMENT | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 59, Pg. 355, 1963. |
guinea pig | LD50 | subcutaneous | 192mg/kg (192mg/kg) | PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE BEHAVIORAL: EXCITEMENT | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 59, Pg. 355, 1963. |
hamster | LDLo | intraperitoneal | 350mg/kg (350mg/kg) | CARDIAC: OTHER CHANGES | Medecine Vol. 9, Pg. 59, 1930. |
human | TDLo | intradermal | 5700ng/kg (0.0057mg/kg) | PERIPHERAL NERVE AND SENSATION: LOCAL ANESTHETIC | Journal of Pharmacology and Experimental Therapeutics. Vol. 76, Pg. 295, 1942. |
mouse | LD50 | intraperitoneal | 242mg/kg (242mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 158, Pg. 135, 1967. | |
mouse | LD50 | intravenous | 95mg/kg (95mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 95, Pg. 336, 1949. | |
mouse | LD50 | oral | 400mg/kg (400mg/kg) | Journal of Medicinal Chemistry. Vol. 9, Pg. 966, 1966. | |
mouse | LD50 | subcutaneous | 40870ug/kg (40.87mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT | Journal of Pharmacology and Experimental Therapeutics. Vol. 87, Pg. 214, 1946. |
mouse | LDLo | parenteral | 500mg/kg (500mg/kg) | Manshu Igaku Zasshi. Manchuria Medical Journal. Vol. 3, Pg. 1, 1925. | |
rabbit | LD50 | intramuscular | 175mg/kg (175mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 86, Pg. 284, 1946. | |
rabbit | LD50 | intravenous | 65mg/kg (65mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 95, Pg. 336, 1949. | |
rabbit | LD50 | subcutaneous | 165mg/kg (165mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 86, Pg. 284, 1946. | |
rat | LD50 | intraperitoneal | 165mg/kg (165mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 86, Pg. 284, 1946. | |
rat | LD50 | intravenous | 69mg/kg (69mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 33, Pg. 80, 1944. | |
rat | LD50 | subcutaneous | 1150mg/kg (1150mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 95, Pg. 336, 1949. |